Plain-English translation of NCT06821958 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether combining electromagnetic field therapy with double immune checkpoint inhibition—a type of immunotherapy that helps your immune system fight cancer—can be effective and safe for people with advanced hepatocellular carcinoma (liver cancer). Right now, doctors use the immunotherapy alone, but researchers want to see if adding the electromagnetic field treatment might help patients do even better. The electromagnetic field therapy is a non-invasive treatment that uses special energy waves to target cancer cells.
While there is some older data suggesting that electromagnetic field therapy might help with various solid tumors including liver cancer, there has never been a formal study testing this combination of treatments together in patients with advanced liver cancer. This trial will help doctors understand whether adding this therapy to immunotherapy is both safe and helpful.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the standard immune checkpoint inhibition treatment (two types of antibody medications) as planned. In addition, you will come to the hospital twice per week for electromagnetic field therapy sessions, each lasting about 60 minutes, where you will lie flat while the treatment is delivered. The trial will monitor your health, cancer response, and any side effects throughout your treatment.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Germany
Sponsor
Charite University, Berlin, Germany
Enrollment target
~36 participants
Started
March 2025
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Pirus Ghadjar, Prof. Dr.
Charite University, Berlin, Germany
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.